Australia’s Prana Misses Primary Endpoint In POC Alzheimer’s Disease Trial; Stock Tanks
This article was originally published in PharmAsia News
Executive Summary
Prana’s lead Alzheimer’s candidate fails both primary and secondary endpoints in Alzheimer’s proof-of-concept- trial, but the company still has hopes that an extension study will show a stronger signal.